Biomedical subjects

Harold Mitty

Publications and source records attributed to Harold Mitty.

3 recordsLinked to original sources

PubMed2006

Preoperative selective venous sampling for nonlocalizing parathyroid adenomas.

INTRODUCTION: Preoperative parathyroid adenoma localization allows for a minimally invasive surgical approach. Current methods used for adenoma localization include ultrasound, sestamibi scan, and occasionally magnetic resonance imaging (MRI). In cases in which an adenoma is not localized after a radiologic work-up, the surgeon must perform a four-gland exploration. Preoperative selective venous sampling (SVS) has been described as a safe and clinically effective method to localize a parathyroid adenoma after failed exploration. The purpose of this study was to evaluate the efficacy of SVS as a primary localization technique in cases where conventional localization techniques have failed. MATERIALS AND METHODS: Fourteen patients with nonlocalizing parathyroid adenomas after ultrasonography, sestamibi scanning, and MRI were retrospectively reviewed. Eight patients underwent SVS prior to surgery and six patients underwent a four-gland neck exploration without preoperative SVS. The two groups were assessed for accuracy of the SVS in localizing the adenoma, operative time, length of hospitalization, and complications. RESULTS: All of the patients in the study underwent successful uncomplicated surgical parathyroidectomy. The SVS proved accurate in preoperatively localizing the adenoma in 7 of 8 patients and allowed for a minimally invasive approach in 87% of patients. The mean operative time was 33 minutes for the SVS group and 67 minutes in the non-SVS group. None of the patients in either group experienced procedural complications. CONCLUSION: This study suggests that preoperative SVS may represent a safe and effective method of preoperatively localizing the nonlocalized parathyroid adenoma. In cases where conventional radiologic techniques fail to localize an adenoma, SVS may obviate the need for a four-gland exploration.

Adult↗

PubMed2004

Minimally invasive management of an advanced abdominal pregnancy.

BACKGROUND: Advanced abdominal pregnancy is a rare, life-threatening condition that presents a number of challenges. CASE: A 29-year-old primigravida with 10 years of secondary infertility and a previous tuboplasty had a 21-week abdominal pregnancy treated with preoperative arterial embolization before laparoscopically assisted fetal delivery. Postoperatively, 4 cycles of methotrexate were administered at 50 mg/m2 intramuscularly every 3 weeks for the retained abdominal placenta. Subsequent spontaneous conception occurred, and a live, full-term infant was delivered by cesarean delivery 17 months later. No adverse sequelae were found during long-term follow-up. CONCLUSION: This report demonstrates successful minimally invasive management of an advanced abdominal pregnancy with a multimodal approach that included preoperative arterial embolization, laparoscopically assisted delivery, and judicious use of postoperative methotrexate.

Adult↗

PubMed2003

Endovascular stent graft repair of abdominal and thoracic aortic aneurysms: a ten-year experience with 817 patients.

OBJECTIVE: On November 23, 1992, the first endovascular stent graft (ESG) repair of an aortic aneurysm was performed in North America. Following the treatment of this patient, we have continued to evaluate ESG over the past 10 years in the treatment of 817 patients. SUMMARY AND BACKGROUND DATA: Abdominal (AAA) or thoracic (TAA) aortic aneurysms are a significant health concern traditionally treated by open surgical repair. ESG therapy may offer protection from aneurysm rupture with a reduction in procedure morbidity and mortality. METHODS: Over a 10-year period, 817 patients were treated with ESGs for AAA (723) or TAA (94). Patients received 1 of 12 different stent graft devices. Technical and clinical success of ESGs was reviewed, and the incidence of procedure-related complications was analyzed. RESULTS: The mean age was 74.3 years (range, 25-95 years); 678 patients (83%) were men; 86% had 2 or more comorbid medical illnesses, 67% of which included coronary artery disease. Technical success, on an intent-to-treat basis was achieved in 93.8% of patients. Primary clinical success, which included freedom from aneurysm-related death, type I or III endoleak, graft infection or thrombosis, rupture, or conversion to open repair was 65 +/- 6% at 8 years. Of great importance, freedom from aneurysm rupture after ESG insertion was 98 +/- 1% at 9 years. There was a 2.3% incidence of perioperative mortality. One hundred seventy five patients died of causes not related to their aneurysm during a mean follow-up of 15.4 months. CONCLUSIONS: Stent graft therapy for aortic aneurysms is a valuable alternative to open aortic repair, especially in older sicker patients with large aneurysms. Continued device improvements coupled with an enhanced understanding of the important role of aortic pathology in determining therapeutic success will eventually permit ESGs to be a more durable treatment of aortic aneurysms.

Adult↗